RnRMarketResearch.com adds “Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth” new report on its database
GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.
The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.
A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II
The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.
Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.
Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market
Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.
Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.
Comprehensive Table of Contents and more on the report @ http://www.rnrmarketresearch.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-market-report.html
GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.
The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.
A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II
The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.
Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.
Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market
Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.
Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.
Comprehensive Table of Contents and more on the report @ http://www.rnrmarketresearch.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-market-report.html